LVR-Klinikum Düsseldorf Hospital of the Heinrich-Heine University ...

LVR-KLINIKUM DÜsseLDORF – hOsPITaL OF The heINRIch-heINe UNIVeRsITY DÜsseLDORF
Serum prolactin (µIU/ml)
as well as Professor Hippius and Dr. Grohmann (Munich).
The system is used to record clinically significant severe
side effects. All recorded cases are discussed in central
conferences, and the correlation between undesirable
effects and the medication administered is evaluated. Biannual
investigations of census samples allow a comparative
estimation of the relative frequency of undesirable drug
side effects for various psychotropic drugs. In addition, case
documentation is used for the casuistic analysis of unusual,
new side effects.
104
400
360
320
280
240
200
160
800
400
250
200
150
100
50
0
-50
Change in prolactin level (µIU/ml) 1.200
Comparison group
Patients
120 -40 -20 0 20 40 60 80 100 120 140
Time (min)
Control group Unmedicated Medicated
(n=12) (n=6) (n=14)
Serum cortisol (ng/ml)
200
180
160
140
120
100
80
Comparison group
Patients
60 -40 -20 0 20 40 60 80 100 120 140
Time (min)
Figure 21: Serum hormone concentration (A, B) and maximum individual change in hormone levels after clomipramine infusion (C, D) prolactin (A, C) and cortisol
(B, D) in control groups as well as patients in remission after an acute manic-depressive illness or depression, before and after the end of psychopharmaceutical
treatment (unmedicated vs. medicated). Figure modified after Cordes et al., Depression and Anxiety 2009; 26:E111-E119.
Change in cortisol level (µIU/ml)
200
150
100
50
0
-50
Control group Unmedicated Medicated
(n=12) (n=6) (n=14)
Prevention of weight gain and metabolic changes during
treatment with olanzapine: a randomised clinical trial
J. Cordes, J. Thünker, A. Klimke, H. Hauner, B. Schuler,
H. Franken-Rugies, C. Humpf
Project period: 2005–2007
Financing: Lilly GmbH Deutschland
A total of 100 persons with schizophrenia newly treated with
olanzapine were included. After four weeks of screening,
participants were randomised into two groups: a prevention
group (n=36), which participated in a psychoeducative weight
management programme, and a control group (n=38), which